<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01600482</url>
  </required_header>
  <id_info>
    <org_study_id>CIP-TS-003</org_study_id>
    <nct_id>NCT01600482</nct_id>
  </id_info>
  <brief_title>Clinical Investigation for Safety and Efficacy Study of CELT ACD (Arterial ClosureDevice)</brief_title>
  <official_title>Clinical Investigation Plan (CIP) for Safety and Efficacy Study of Arterial Closure Device (CELT ACD). Clinical Investigation Plan No.: CIP-TS-003</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vasorum Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vasorum Ltd</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the CELT ACD® Vascular Closure Device study is to evaluate the safety and
      effectiveness of the CELT ACD® device to achieve hemostasis of the common femoral artery
      access site in patients on anticoagulation who are undergoing a percutaneous intervention
      (PCI) procedure using a 6F sheath.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Safety Endpoint Will be the Combined Rate of Major Complications With in 30 +/- 7 Days Following the Percutaneous Coronary Intervention (PCI) Procedure.</measure>
    <time_frame>With in the first 30 days +/- 7 days following the procedure</time_frame>
    <description>rate of major complications with in 30 +/- 7 days following the PCI procedure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Primary Effectiveness Endpoint Will be Time to Hemostasis (TTH)</measure>
    <time_frame>With in the first 30 days +/- 7 days following the procedure</time_frame>
    <description>Time to hemostasis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Secondary Safety Endpoint Will be the Combined Rate of Minor Complications With in 30 +/- 7 Days Following Procedure.</measure>
    <time_frame>With in the first 30 days +/- 7 days following the procedure</time_frame>
    <description>combined rate of minor complications with in 30 +/- 7 days following procedure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Ambulation</measure>
    <time_frame>With in the first 30 days +/- 7 days following the procedure</time_frame>
    <description>Time to Ambulation (TTA) is defined as the time elapsed between sheath removal and time when the patient stands and walk 6m (20ft) without re-bleeding.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Discharge-ability</measure>
    <time_frame>30 days +/- 7 days</time_frame>
    <description>Time to discharge-ability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure Success</measure>
    <time_frame>30 days +/- 7 days</time_frame>
    <description>Procedure Success 30 days +/- 7 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>30 days +/- 7 days</time_frame>
    <description>Device Success (DS) is defined as the successful deployment of the Celt ACD device with the attainment of haemostasis and only assessed in the Celt ACD arm of the study.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">241</enrollment>
  <condition>Cardiac Disease</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CELT ACD device</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The CELT ACD device is a vascular closure device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Manual Compression</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Manual Compression</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CELT ACD</intervention_name>
    <description>The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.</description>
    <arm_group_label>CELT ACD device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over 18 years of age.

          2. Each patient, or his or her guardian or legal representative, is willing to give
             informed consent.

          3. Clinically indicated for an intra-arterial procedure involving access through the
             common femoral artery and conducted through an access sheath size of between 6F and 7F
             inclusive.

        Exclusion Criteria:

          1. Patients with known allergy to any of the materials used in the device.

          2. Severe acute non-cardiac systemic disease or terminal illness with a life expectancy
             of less than one year.

          3. Evidence of systemic bacterial or cutaneous infection, including groin infection.

          4. Patients suffering with definitive or potential coagulopathy or platelet count
             &lt;100,000./µl

          5. Use of systemic thrombolytic agents within 24 hours prior to or during the
             catheterization procedure which cause the concentration of fibrinogen to be &lt; 100
             mg/dl or if post-thrombolytic fibrinogen (in case of thrombolysis within 24 hours or
             intra-procedural) cannot be measured.

          6. Patients in whom an introducer sheath smaller than 6F or greater than 7F have been
             used.

          7. Currently participating in another investigational device or drug study.

          8. Patients with severe claudication, iliac or femoral artery diameter stenosis greater
             than 50%, or previous bypass surgery or stent placement in the vicinity of the access
             site.

          9. If puncture site is via a vascular graft.

         10. If a palpable haematoma is observed during the procedure.

         11. Patients in whom there is any indication that puncture has been made in the profunda
             femorals artery or superficial femoral artery, or adjacent to the bifurcation.

         12. Patients with a common femoral artery lumen diameter of less than 5 mm.

         13. Patients that have any amputation from an access site limb.

         14. Patients that have undergone a percutaneous procedure using a vascular closure device
             for hemostasis within the previous 30 days or using manual/mechanical pressure for
             hemostasis within the prior 30 days in the same leg.

         15. Patients with a systolic blood pressure reading below 90 mmHg.

         16. Patients with an active haematoma, arteriovenous fistula, or pseudoaneurysm.

         17. Patients with a very superficial artery where the depth from skin to the artery
             surface at the access site is less than 4 mm.

         18. Morbidly obese patients (Body Mass Index &gt;35kg/m2).

         19. Patients with a stent less than or equal to 1 cm of the puncture site that would
             interfere with placement of the device implant.

         20. Patient is know or suspected to be pregnant, or is lactating.

         21. Patients in whom there has been an antegrade puncture.

         22. Patients in whom there has been difficulty in obtaining vascular access resulting in
             multiple arterial punctures and/or posterior arterial wall puncture.

         23. Patients who have undergone prior or recent use of an intra-aortic balloon pump
             through the arterial access site.

         24. Patients with uncontrolled hypertension (BP greater than or equal to 180/110mmHg) at
             time of vascular closure

         25. Patients with acute ST-elevation myocardial infarction less than or equal to 48hours
             before catheterization procedure.

         26. Patients with cardiogenic shock (hemodynamic instability requiring intravenous
             medication or mechanical support) experienced during or immediately
             post-catheterization.

         27. Patients who are unable to ambulate at baseline.

         28. Patients known to require an extended hospitalization (e.g. patient is undergoing
             cardiac surgery).

         29. Patient has already participated in the trial.

         30. Patient is unavailable for follow up.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Presbyterian Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Städtische Kliniken Neuss - Lukaskrankenhaus - GmbH</name>
      <address>
        <city>Preußenstr. 84,41464 Neuss</city>
        <state>Neuss</state>
        <zip>41464 Neuss</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Campus Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Galway University Hosptial</name>
      <address>
        <city>Galway</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Ireland</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 16, 2012</study_first_submitted>
  <study_first_submitted_qc>May 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2012</study_first_posted>
  <results_first_submitted>May 16, 2017</results_first_submitted>
  <results_first_submitted_qc>July 24, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">August 23, 2017</results_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hemostasis.</keyword>
  <keyword>Percutaneous coronary interventions.</keyword>
  <keyword>Closure Device</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>As per agreement with FDA, following the 207 patient 6F Celt ACD study, an additional 34 patients were recruited across 3 clinical investigation sites whereby a 7F Celt ACD device was used to close an arterial puncture made with a 7F sheath in fully anti-coagulated patients. 7F device approval is pending with FDA.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>CELT ACD Device</title>
          <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
        </group>
        <group group_id="P2">
          <title>Manual Compression</title>
          <description>Manual Compression</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="148"/>
                <participants group_id="P2" count="59">Last 26 patients allocated to CELT ACD</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="148">Last 26 patients allocated to CELT ACD</participants>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CELT ACD Device</title>
          <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
        </group>
        <group group_id="B2">
          <title>Manual Compression</title>
          <description>Manual Compression</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="148"/>
            <count group_id="B2" value="59"/>
            <count group_id="B3" value="207"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.75" spread="10.8"/>
                    <measurement group_id="B2" value="67.44" spread="11.7"/>
                    <measurement group_id="B3" value="66.95" spread="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="159"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ireland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>Kgs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85.38" spread="16.22"/>
                    <measurement group_id="B2" value="82.78" spread="40.83"/>
                    <measurement group_id="B3" value="84.65" spread="15.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.90" spread="9.56"/>
                    <measurement group_id="B2" value="171.70" spread="7.82"/>
                    <measurement group_id="B3" value="172.50" spread="9.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27.75" spread="4.47"/>
                    <measurement group_id="B2" value="28.18" spread="4.41"/>
                    <measurement group_id="B3" value="27.87" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Right Femoral Artery Site</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="148"/>
                    <count group_id="B2" value="59"/>
                    <count group_id="B3" value="207"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="142"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Safety Endpoint Will be the Combined Rate of Major Complications With in 30 +/- 7 Days Following the Percutaneous Coronary Intervention (PCI) Procedure.</title>
        <description>rate of major complications with in 30 +/- 7 days following the PCI procedure.</description>
        <time_frame>With in the first 30 days +/- 7 days following the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CELT ACD Device</title>
            <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
          </group>
          <group group_id="O2">
            <title>Manual Compression</title>
            <description>Manual Compression</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Safety Endpoint Will be the Combined Rate of Major Complications With in 30 +/- 7 Days Following the Percutaneous Coronary Intervention (PCI) Procedure.</title>
          <description>rate of major complications with in 30 +/- 7 days following the PCI procedure.</description>
          <units>major complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Primary Effectiveness Endpoint Will be Time to Hemostasis (TTH)</title>
        <description>Time to hemostasis</description>
        <time_frame>With in the first 30 days +/- 7 days following the procedure</time_frame>
        <population>7 subjects in manual compression group where TTH was not recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>CELT ACD Device</title>
            <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
          </group>
          <group group_id="O2">
            <title>Manual Compression</title>
            <description>Manual Compression</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Effectiveness Endpoint Will be Time to Hemostasis (TTH)</title>
          <description>Time to hemostasis</description>
          <population>7 subjects in manual compression group where TTH was not recorded.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.99" spread="4.15"/>
                    <measurement group_id="O2" value="17.54" spread="54.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Secondary Safety Endpoint Will be the Combined Rate of Minor Complications With in 30 +/- 7 Days Following Procedure.</title>
        <description>combined rate of minor complications with in 30 +/- 7 days following procedure.</description>
        <time_frame>With in the first 30 days +/- 7 days following the procedure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>CELT ACD Device</title>
            <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
          </group>
          <group group_id="O2">
            <title>Manual Compression</title>
            <description>Manual Compression</description>
          </group>
        </group_list>
        <measure>
          <title>The Secondary Safety Endpoint Will be the Combined Rate of Minor Complications With in 30 +/- 7 Days Following Procedure.</title>
          <description>combined rate of minor complications with in 30 +/- 7 days following procedure.</description>
          <units>minor complications</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Ambulation</title>
        <description>Time to Ambulation (TTA) is defined as the time elapsed between sheath removal and time when the patient stands and walk 6m (20ft) without re-bleeding.</description>
        <time_frame>With in the first 30 days +/- 7 days following the procedure</time_frame>
        <population>62 patients did not have TTA recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>CELT ACD Device</title>
            <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
          </group>
          <group group_id="O2">
            <title>Manual Compression</title>
            <description>Manual Compression</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Ambulation</title>
          <description>Time to Ambulation (TTA) is defined as the time elapsed between sheath removal and time when the patient stands and walk 6m (20ft) without re-bleeding.</description>
          <population>62 patients did not have TTA recorded.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="101"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="360.0" spread="418.4"/>
                    <measurement group_id="O2" value="406.4" spread="216.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Discharge-ability</title>
        <description>Time to discharge-ability</description>
        <time_frame>30 days +/- 7 days</time_frame>
        <population>107 did not have time to dischargeability data collected.</population>
        <group_list>
          <group group_id="O1">
            <title>CELT ACD Device</title>
            <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
          </group>
          <group group_id="O2">
            <title>Manual Compression</title>
            <description>Manual Compression</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Discharge-ability</title>
          <description>Time to discharge-ability</description>
          <population>107 did not have time to dischargeability data collected.</population>
          <units>Minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="662.51" spread="511.70"/>
                    <measurement group_id="O2" value="511.76" spread="350.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Procedure Success</title>
        <description>Procedure Success 30 days +/- 7 days</description>
        <time_frame>30 days +/- 7 days</time_frame>
        <population>7 patients were excluded in Manual Compression group as there was no TTH data recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>CELT ACD Device</title>
            <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
          </group>
          <group group_id="O2">
            <title>Manual Compression</title>
            <description>Manual Compression</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Success</title>
          <description>Procedure Success 30 days +/- 7 days</description>
          <population>7 patients were excluded in Manual Compression group as there was no TTH data recorded.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="52"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Device Success</title>
        <description>Device Success (DS) is defined as the successful deployment of the Celt ACD device with the attainment of haemostasis and only assessed in the Celt ACD arm of the study.</description>
        <time_frame>30 days +/- 7 days</time_frame>
        <population>7 patients in the MP group did not have TTH recorded.</population>
        <group_list>
          <group group_id="O1">
            <title>CELT ACD Device</title>
            <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
          </group>
          <group group_id="O2">
            <title>Manual Compression</title>
            <description>Manual Compression</description>
          </group>
        </group_list>
        <measure>
          <title>Device Success</title>
          <description>Device Success (DS) is defined as the successful deployment of the Celt ACD device with the attainment of haemostasis and only assessed in the Celt ACD arm of the study.</description>
          <population>7 patients in the MP group did not have TTH recorded.</population>
          <units>Number of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="148"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days +/- 7 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CELT ACD Device</title>
          <description>The CELT ACD device is a vascular closure device.
CELT ACD: The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous coronary intervention procedure using either a 6F or a 7F procedural sheath.</description>
        </group>
        <group group_id="E2">
          <title>Manual Compression</title>
          <description>Manual Compression</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Device migration</sub_title>
                <description>Device migration from femoral artery access point</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="148"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="59"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <description>Syncope during the follow up period</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Brain Stem Ischemia</sub_title>
                <description>Brain stem ischemia unrelated to procedure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="148"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="59"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr James Coleman</name_or_title>
      <organization>Vasorum Ltd</organization>
      <phone>00 353 1 4035460</phone>
      <email>jcoleman@vasorum.ie</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

